CUVL · Clinuvel Pharmaceuticals Ltd ADR
United States · RS rating 13 · As of 2026-10-14
| Price | 5.30 USD |
|---|---|
| 1-day change | -2.6% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 23 / 14 / 19 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 6 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +39.4% |
| Market cap (USD) | $361.6M |